Announcements Trials
Browse Landscape

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Observational 2

Sponsor

Cancer Type

Tumor-Agnostic 2

Conditions

Neoplasms 2Xeroderma Pigmentosum 1Sebaceous Cell Tumor of Eyelid 1Prostatic Neoplasms 1Hereditary Cancer 1Adenocarcinoma 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 99Fluorouracil 90Capecitabine 86Radiotherapy 81Dexamethasone 81Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Drug Therapy 65Leucovorin 64Cetuximab 60Erlotinib Hydrochloride 56atezolizumab 53Sorafenib 53Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × Longitudinal Studies × Clear all
NCT06270602 2025-12-22

The ONCOCAMP Study

National Cancer Institute, Naples

Recruiting
15,000 enrolled
Tumor-Agnostic

Neoplasms

NCT02159742 2025-07-02

Prospective Follow-up of Outcomes in Patients Receiving Photodynamic Therapy for Neoplastic Diseases

Abramson Cancer Center at Penn Medicine

Active not recruiting
400 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡